Boletín de AInvest
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
INOVIO Pharmaceuticals has priced an underwritten public offering of 14.29 million shares of common stock and accompanying warrants to purchase up to 14.29 million shares at $1.75 per share. The offering is expected to close on July 7, 2025, with all securities being sold by INOVIO. The funds raised will support the development and commercialization of DNA medicines for HPV-related diseases, cancer, and infectious diseases.
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Comentarios
Aún no hay comentarios